| Section 1: Ischemic Stroke |
|
|
|
|
|
|
|
|
1 Intravenous tPA for Acute Ischemic Stroke |
|
|
2 | (2) |
|
2 Aspirin for Secondary Stroke Prevention |
|
|
4 | (2) |
|
3 Mechanical Thrombectomy for Large Vessel Occlusion |
|
|
6 | (2) |
|
4 Harm from Stenting of Symptomatic Intracranial Arterial Stenoses |
|
|
8 | (2) |
|
5 Warfarin for Atrial Fibrillation |
|
|
10 | (2) |
|
6 Novel Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation |
|
|
12 | (2) |
|
7 Intense Low-Density Lipoprotein Cholesterol Reduction for Stroke Prevention |
|
|
14 | (2) |
|
8 Marginal Benefit from Device Closure of Patent Foramen Ovale |
|
|
16 | (2) |
|
9 Early Decompressive Surgery in Malignant Infarction of the Middle Cerebral Artery |
|
|
18 | (2) |
|
10 Carotid Endarterectomy for Stroke Prevention in Internal Carotid Artery Stenosis |
|
|
20 | (2) |
|
11 Carotid Artery Stenting vs. Carotid Endarterectomy For Symptomatic and Asymptomatic Carotid Artery Stenosis |
|
|
22 | (2) |
|
12 Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm |
|
|
24 | (2) |
|
13 Short-Term Dual Antiplatelet Therapy for Stroke Prevention after TIA or Minor Stroke |
|
|
26 | (4) |
|
14 Aspirin Over Warfarin for Symptomatic Intracranial Stenosis |
|
|
30 | (4) |
|
15 Lack of Benefit from Long-Term Dual Antiplatelet Therapy for Secondary Stroke Prevention |
|
|
34 | (2) |
|
16 Fluoxetine for Motor Recovery after Acute Ischemic Stroke |
|
|
36 | (2) |
|
17 Carotid Endarterectomy for Asymptomatic Carotid Artery Stenosis |
|
|
38 | (4) |
|
18 Extended Monitoring for Paroxysmal Atrial Fibrillation |
|
|
42 | (2) |
|
19 The National Institutes of Health Stroke Scale |
|
|
44 | (4) |
| Section 2: Cerebral Hemorrhage |
|
|
|
|
|
|
|
|
20 Blood Pressure Regulation in Parenchymal Intracerebral Hemorrhage |
|
|
48 | (2) |
|
21 Early Surgery for Spontaneous Intracerebral Hemorrhage and Hydrocephalus |
|
|
50 | (2) |
|
22 Avoidance of Long-Term Anticoagulation for Atrial Fibrillation after Intracerebral Hemorrhage |
|
|
52 | (2) |
|
23 Nimodipine for Prevention of Delayed Neurologic Injury after Subarachnoid Hemorrhage |
|
|
54 | (2) |
|
24 Inferiority of Surgical Resection to Medical Management of Unruptured AVM |
|
|
56 | (2) |
|
25 Prognostication for Intracerebral Hemorrhage |
|
|
58 | (2) |
|
26 Acute Endovascular Treatment for Ruptured Subarachnoid Hemorrhage |
|
|
60 | (2) |
|
27 Neurosurgical Clipping vs. Endovascular Coiling of Ruptured Intracranial Aneurysms |
|
|
62 | (2) |
|
28 Withdrawal of Support in Intracerebral Hemorrhage because of Predicted Poor Prognosis May Lead to Self-Fulfilling Prophecy |
|
|
64 | (2) |
|
29 rtPA for Intraventricular Hemorrhage |
|
|
66 | (2) |
|
30 Grading of Ruptured Subarachnoid Hemorrhages |
|
|
68 | (4) |
| Section 3: Traumatic Brain Injury |
|
|
|
|
|
|
|
|
72 | (2) |
|
32 Albumin vs. Saline for Resuscitation after Traumatic Brain Injury |
|
|
74 | (2) |
|
33 Decompressive Craniectomy in Traumatic Brain Injury |
|
|
76 | (4) |
|
34 Antiepileptic Drugs after Traumatic Brain Injury |
|
|
80 | (2) |
|
35 Intracranial Pressure Monitoring in Traumatic Brain Injury |
|
|
82 | (2) |
|
36 Amantadine for Recovery of Consciousness after Traumatic Brain Injury |
|
|
84 | (2) |
|
37 Functional Imaging in Vegetative States |
|
|
86 | (4) |
|
38 Corticosteroids for Traumatic Brain Injury |
|
|
90 | (2) |
|
39 Corticosteroids in Acute Spinal Cord Injury |
|
|
92 | (6) |
| Section 4: Neurologic Intensive Care |
|
|
|
|
|
|
40 Midline Shift and Level of Consciousness |
|
|
98 | (2) |
|
41 Use of Hyperosmolar Therapy for Cerebral Edema |
|
|
100 | (4) |
|
42 Hyperventilation for Acute Intracranial Pressure Elevation |
|
|
104 | (2) |
|
43 Temperature Management for Cardiac Arrest in Adults |
|
|
106 | (4) |
|
44 Early Mobilization in the Intensive Care Unit |
|
|
110 | (4) |
| Section 5: Neuroinfectious Diseases |
|
|
|
|
|
|
45 Glucocorticoids for Bacterial Meningitis in Adults |
|
|
114 | (4) |
|
46 Acyclovir for Herpes Simplex Encephalitis |
|
|
118 | (2) |
|
47 Polymerase Chain Reaction Testing for Herpes Simplex Encephalitis |
|
|
120 | (2) |
|
48 Antifungal Therapy for Cryptococcal Meningitis |
|
|
122 | (2) |
|
49 Guidelines for Treatment of Lyme Disease in the Nervous System |
|
|
124 | (4) |
| Section 6: Neuro-Oncology |
|
|
|
|
|
|
50 Temozolomide for Glioblastoma |
|
|
128 | (2) |
|
51 Surgery for Brain Metastases |
|
|
130 | (2) |
|
52 Chemotherapy for Low-Grade Glioma |
|
|
132 | (2) |
|
53 NovoTTF for Newly Diagnosed Glioblastoma |
|
|
134 | (2) |
|
54 Bevacizumab for Recurrent Glioblastoma |
|
|
136 | (2) |
|
55 Methotrexate for Primary CNS Lymphoma |
|
|
138 | (4) |
| Section 7: Neuromuscular |
|
|
|
|
|
|
56 Acute Treatment for Guillain-Barre Syndrome |
|
|
142 | (2) |
|
57 Alternate Day Prednisone in Myasthenia Gravis |
|
|
144 | (2) |
|
58 IVIg vs. Prednisone for Chronic Inflammatory Demyelinating Polyneuropathy |
|
|
146 | (2) |
|
59 Glucocorticoid Steroids for Duchenne Muscular Dystrophy |
|
|
148 | (2) |
|
60 Riluzole in Amyotrophic Lateral Sclerosis |
|
|
150 | (2) |
|
61 Thymectomy in Myasthenia Gravis |
|
|
152 | (4) |
| Section 8: Movement Disorders |
|
|
|
|
|
|
62 L-Dopa for Parkinson's Disease |
|
|
156 | (2) |
|
63 Deep Brain Stimulation for Parkinson's Disease |
|
|
158 | (2) |
|
64 Deep Brain Stimulation for Dystonia |
|
|
160 | (2) |
|
65 L-Dopa vs. MAO-B Inhibitors in Parkinson's Disease |
|
|
162 | (2) |
|
66 Propranolol Treatment for Essential Tremor |
|
|
164 | (2) |
|
67 Rasagiline in Parkinson's Disease |
|
|
166 | (2) |
|
68 Botulinum a Toxin for Dystonia |
|
|
168 | (4) |
| Section 9: Multiple Sclerosis |
|
|
|
|
|
|
69 Progressive Multifocal Leukoencephalopathy after Treatment with Natalizumab |
|
|
172 | (2) |
|
70 Glucocorticoids for Optic Neuritis: The Optic Neuritis Treatment Trial |
|
|
174 | (2) |
|
71 Neuromyelitis Optica Antibody in the Diagnosis of Neuromyelitis Optica |
|
|
176 | (2) |
|
72 Correlation Between MRI Findings and Disability in Multiple Sclerosis |
|
|
178 | (2) |
|
73 The Association of Vitamin D Levels and Multiple Sclerosis |
|
|
180 | (2) |
|
74 Rate of Pregnancy-Related Relapse in Multiple Sclerosis |
|
|
182 | (4) |
| Section 10: Autoimmune Neurology |
|
|
|
|
|
|
75 EULAR Recommendations for Treatment of Primary CNS Vasculitis |
|
|
186 | (4) |
|
76 NMDA-ab Receptor Encephalitis with Ovarian Teratoma |
|
|
190 | (4) |
|
77 Identification of Sjogren's Syndrome Associated Ganglionopathy |
|
|
194 | (2) |
|
78 IVIG for Stiff Person Syndrome |
|
|
196 | (4) |
| Section 11: Epilepsy |
|
|
|
|
|
|
79 Lorazepam for Treatment of Status Epilepticus |
|
|
200 | (2) |
|
80 Magnesium for the Prevention of Eclampsia |
|
|
202 | (2) |
|
81 Antiepileptic Drug Treatment after a First Unprovoked Seizure |
|
|
204 | (2) |
|
82 Intravenous vs. Intramuscular Benzodiazepines for Status Epilepticus |
|
|
206 | (2) |
|
83 Continuous EEG Monitoring for Evaluation of Nonconvulsive Status Epilepticus |
|
|
208 | (4) |
| Section 12: Headache And Pain |
|
|
|
|
|
|
84 Sumatriptan for Migraine |
|
|
212 | (2) |
|
85 Topiramate for Migraine Prevention |
|
|
214 | (2) |
|
86 Duloxetine for Chemo-Induced Painful Neuropathy |
|
|
216 | (2) |
|
87 Pregabalin for Neuropathic Pain |
|
|
218 | (2) |
|
88 Amitriptyline Prophylaxis for Headache |
|
|
220 | (2) |
|
89 Divalproex for Migraine Prophylaxis |
|
|
222 | (4) |
| Section 13: Cognitive Neurology |
|
|
|
|
|
|
90 Donepezil for Alzheimer's Disease |
|
|
226 | (2) |
|
91 Memantine in Addition to Donepezil for Alzheimer's Disease |
|
|
228 | (2) |
|
92 Rivastigmine for Dementia with Lewy Bodies |
|
|
230 | (4) |
|
93 Melatonin for REM Sleep Behavior Disorder |
|
|
234 | (2) |
|
|
|
236 | (4) |
| Section 14: Pediatric Neurology |
|
|
|
|
|
|
95 Treatment of Infantile Spasms |
|
|
240 | (2) |
|
96 Pharmaco vs. Behavioral Therapy for ADHD |
|
|
242 | (2) |
|
97 Ketogenic Diet for the Treatment of Childhood Epilepsy |
|
|
244 | (2) |
|
98 Hypothermia for Neonates with Hypoxic-Ischemic Encephalopathy |
|
|
246 | (2) |
|
|
|
248 | (2) |
|
100 When to Stop Antiepileptic Drugs in Children with Epilepsy |
|
|
250 | (3) |
| Index |
|
253 | |
